T3X.F Telix Pharmaceuticals Limited

Healthcare Biotechnology Frankfurt Exchange
8.59 EUR
Close of Nov 12, 2026
5.03 11.50
Market cap
EUR 2.92B
P/E
107.4x
P/B
6.50x
ROE
-1.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is T3X.F undervalued?

Graham number

The Graham number of Telix Pharmaceuticals Limited cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Telix Pharmaceuticals Limited fundamental analysis

No fundamental analysis for Telix Pharmaceuticals Limited yet.

Telix Pharmaceuticals Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The co…

Full company profile